Literature DB >> 27654294

The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.

Elena Wüstenhagen1, Laura Hampe1, Fatima Boukhallouk1, Marc A Schneider1,2, Gilles A Spoden1, Inka Negwer3, Kaloian Koynov3, W Martin Kast4, Luise Florin5.   

Abstract

The human papillomavirus (HPV) capsid protein L2 is essential for viral entry. To gain a deeper understanding of the role of L2, we searched for novel cellular L2-interacting proteins. A yeast two-hybrid analysis uncovered the actin-depolymerizing factor gelsolin, the membrane glycoprotein dysadherin, the centrosomal protein 68 (Cep68), and the cytoskeletal adaptor protein obscurin-like 1 protein (OBSL1) as putative L2 binding molecules. Pseudovirus (PsV) infection assays identified OBSL1 as a host factor required for gene transduction by three oncogenic human papillomavirus types, HPV16, HPV18, and HPV31. In addition, we detected OBSL1 expression in cervical tissue sections and noted the involvement of OBSL1 during gene transduction of primary keratinocytes by HPV16 PsV. Complex formation of HPV16 L2 with OBSL1 was demonstrated in coimmunofluorescence and coimmunoprecipitation studies after overexpression of L2 or after PsV exposure. We observed a strong colocalization of OBSL1 with HPV16 PsV and tetraspanin CD151 at the plasma membrane, suggesting a role for OBSL1 in viral endocytosis. Indeed, viral entry assays exhibited a reduction of viral endocytosis in OBSL1-depleted cells. Our results suggest OBSL1 as a novel L2-interacting protein and endocytosis factor in HPV infection. IMPORTANCE: Human papillomaviruses infect mucosal and cutaneous epithelia, and the high-risk HPV types account for 5% of cancer cases worldwide. As recently discovered, HPV entry occurs by a clathrin-, caveolin-, and dynamin-independent endocytosis via tetraspanin-enriched microdomains. At present, the cellular proteins involved in the underlying mechanism of this type of endocytosis are under investigation. In this study, the cytoskeletal adaptor OBSL1 was discovered as a previously unrecognized interaction partner of the minor capsid protein L2 and was identified as a proviral host factor required for HPV16 endocytosis into target cells. The findings of this study advance the understanding of a so far less well-characterized endocytic pathway that is used by oncogenic HPV subtypes.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27654294      PMCID: PMC5110159          DOI: 10.1128/JVI.01222-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70.

Authors:  Luise Florin; Katrin A Becker; Cornelia Sapp; Carsten Lambert; Hüseyin Sirma; Martin Müller; Rolf E Streeck; Martin Sapp
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.

Authors:  Rebecca M Richards; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 3.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

4.  The extracellular δ-domain is essential for the formation of CD81 tetraspanin webs.

Authors:  Yahya Homsi; Jan-Gero Schloetel; Konstanze D Scheffer; Thomas H Schmidt; Nicolas Destainville; Luise Florin; Thorsten Lang
Journal:  Biophys J       Date:  2014-07-01       Impact factor: 4.033

5.  Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.

Authors:  C Leder; J A Kleinschmidt; C Wiethe; M Müller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein.

Authors:  M Sapp; U Kraus; C Volpers; P J Snijders; J M Walboomers; R E Streeck
Journal:  J Gen Virol       Date:  1994-12       Impact factor: 3.891

7.  Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection.

Authors:  Rongcun Yang; William H Yutzy; Raphael P Viscidi; Richard B S Roden
Journal:  J Biol Chem       Date:  2003-01-30       Impact factor: 5.157

8.  Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions.

Authors:  Mario Schelhaas; Helge Ewers; Minna-Liisa Rajamäki; Patricia M Day; John T Schiller; Ari Helenius
Journal:  PLoS Pathog       Date:  2008-09-05       Impact factor: 6.823

9.  Vesicular trafficking of incoming human papillomavirus 16 to the Golgi apparatus and endoplasmic reticulum requires γ-secretase activity.

Authors:  Wei Zhang; Teymur Kazakov; Andreea Popa; Daniel DiMaio
Journal:  mBio       Date:  2014-09-16       Impact factor: 7.867

10.  The CD63-Syntenin-1 Complex Controls Post-Endocytic Trafficking of Oncogenic Human Papillomaviruses.

Authors:  Linda Gräßel; Laura Aline Fast; Konstanze D Scheffer; Fatima Boukhallouk; Gilles A Spoden; Stefan Tenzer; Klaus Boller; Ruzica Bago; Sundaresan Rajesh; Michael Overduin; Fedor Berditchevski; Luise Florin
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

View more
  15 in total

Review 1.  Cruising the cellular highways: How human papillomavirus travels from the surface to the nucleus.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G Guion; Martin Sapp
Journal:  Virus Res       Date:  2016-10-29       Impact factor: 3.303

Review 2.  The long and winding road: human papillomavirus entry and subcellular trafficking.

Authors:  Michelle A Ozbun; Samuel K Campos
Journal:  Curr Opin Virol       Date:  2021-08-17       Impact factor: 7.121

3.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 4.  Subcellular Trafficking of the Papillomavirus Genome during Initial Infection: The Remarkable Abilities of Minor Capsid Protein L2.

Authors:  Samuel K Campos
Journal:  Viruses       Date:  2017-12-03       Impact factor: 5.048

Review 5.  Papillomaviruses Go Retro.

Authors:  Jian Xie; Pengwei Zhang; Mac Crite; Daniel DiMaio
Journal:  Pathogens       Date:  2020-04-07

Review 6.  The endocytic trafficking pathway of oncogenic papillomaviruses.

Authors:  Snježana Mikuličić; Luise Florin
Journal:  Papillomavirus Res       Date:  2019-04-01

7.  ADAM17-dependent signaling is required for oncogenic human papillomavirus entry platform assembly.

Authors:  Snježana Mikuličić; Jérôme Finke; Fatima Boukhallouk; Elena Wüstenhagen; Dominik Sons; Yahya Homsi; Karina Reiss; Thorsten Lang; Luise Florin
Journal:  Elife       Date:  2019-05-20       Impact factor: 8.140

8.  Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation.

Authors:  Julia R Taylor; Daniel J Fernandez; Shantaé M Thornton; Joseph G Skeate; Kim P Lühen; Diane M Da Silva; Ralf Langen; W Martin Kast
Journal:  Sci Rep       Date:  2018-08-03       Impact factor: 4.379

9.  Overexpressed coiled-coil domain containing protein 8 (CCDC8) mediates newly synthesized HIV-1 Gag lysosomal degradation.

Authors:  Xiangxiang Jiang; Xiaopeng Jia; Jinhuan Sun; Chunxia Qi; Lingling Lu; Yanfeng Wang; Lei Zhang; Min Wei
Journal:  Sci Rep       Date:  2020-07-10       Impact factor: 4.379

Review 10.  Papillomaviruses and Endocytic Trafficking.

Authors:  Abida Siddiqa; Justyna Broniarczyk; Lawrence Banks
Journal:  Int J Mol Sci       Date:  2018-09-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.